Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PolyPEPI1018 CRC Vaccine · 1 trial · 1 indication
Occurrence of at least 1 ≥Grade 4 local adverse event (AE) or 1 ≥Grade 3 systemic AE and/or signs/symptoms, lab toxicities, and/or clinical events that is probably or definitely related to study treatment
| Arm | Type | Description |
|---|---|---|
| PolyPEPI1018 CRC Vaccine | EXPERIMENTAL | The vaccine contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. |
| Name | Type | Description |
|---|---|---|
| PolyPEPI1018 CRC Vaccine | BIOLOGICAL | Colorectal Cancer Vaccine |
Inclusion Criteria: 1. Male or female subjects, 18-75 years of age at time of Screening who provide written informed consent prior to initiation of any study procedure 2. Histologically confirmed metastatic adenocarcinoma originating from the colon or the rectum 3. Presence of at least 1 measurable...
Top 20 of 71 competitors